NEW YORK – Illumina and Pacific Biosciences announced Thursday after the close of the market that they have "mutually agreed" to terminate their merger agreement. Next Generation Sequencing (NGS) Market Outlook - 2026. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. This share price information is delayed by 15 minutes. COVID-19 Impact on Global RNA-Seq Market Size, Status and Forecast 2020 The Global RNA-Seq Market Research Report 2021-2026 is a valuable source of insightful data for business strategists. The growth can be attributed to … Revenues reflectNorth America segment decrease of 25% to $25.2M, AsiaPacific segment decrease of 18% to $14.6M. As of PACB earnings call for the period ending December 31, 2019. You can read more about the power of momentum in assessing share price movements on Stockopedia. Pacific Biosciences of California Inc is scheduled to issue upcoming financial results on the following dates: Pacific Biosciences of California Inc does not currently pay a dividend. View which stocks have been most impacted by COVID-19. In 2015 Pacific Biosciences launched its new Sequel system based on SMRT technology. At that level they are trading at 35.2% premium to the analyst consensus target price of 0.00. Of the analysts with advisory recommendations for Pacific Biosciences of California Inc, there are there are currently 0 "buy" , 3 "hold" and 0 "sell" recommendations. The question now for investors is whether that price strength will continue. Global Third-Generation Sequencing Market Size, Status and Forecast 2020-2026. These two small-cap stocks are risky, but not as risky as penny stocks. DNA Sequencing Market Overview: The global DNA sequencing market was valued at $6,243 million in 2017, and is expected to reach $25,470 million in 2025, registering a CAGR of 19.0% from 2018 to 2025. Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The question now for investors is whether that price strength will continue. We were not able to find PE ratio data for Pacific Biosciences of California Inc. Pacific Biosciences of California Inc's management team is headed by: Here are the top five shareholders of Pacific Biosciences of California Inc based on the size of their shareholding: © Stockopedia 2021, Refinitiv, Share Data Services. market position, the CMA also took into account, within the context of the dynamic nature of the market, the evidence that PacBio’s current share of supply does not accurately reflect its competitive significance following the launch of its Sequel II instrument in April 2019. You can view the full broker recommendation list by unlocking its StockReport. CAPS Rating . Pacific Biosciences of California (PACB) Q2 2020 Earnings Call Transcript, Pacific Biosciences of California Inc (PACB) Q1 2020 Earnings Call Transcript, Pacific Biosciences of California Inc (PACB) Q4 2019 Earnings Call Transcript, Here’s Why Illumina Shares Barely Budged When It Gave Up On Its Takeover to The Tune Of $98 Million, About to Buy Penny Stocks? Pacific Biosciences is a leader in the latest generation of human DNA sequencing. Figure 3-2 Product Market Share, 2020 Figure 3-3: Product Market Share, 2025 5. The Competition and Markets Authority (CMA) has been investigating the proposed $1.2 billion merger of Illumina, Inc. (Illumina) and Pacific Biosciences of California, Inc (PacBio… The COVID-19 pandemic continues to negatively impact the gene-sequencing company's sales. The DNA sequencing leader announced upgrades to some of its core offerings. Look At These 2 Companies First, Here's Why Pacific Biosciences Gained as Much as 10.5% Today, Why Pacific Biosciences of California Stock Is Sinking Today, Here's Why Pacific Biosciences Is Tumbling Today, Why Pacific Biosciences of California Stock Is Skyrocketing Today, Why Pacific Biosciences Fell By 10.6% Earlier Today, Here's Why Pacific Biosciences Tumbled 10% Today, Here's Why Pacific Biosciences of California, Inc. Rose 40.3% in June, Copyright, Trademark and Patent Information. The Bottom Line 1305 O'brien Drive, MENLO PARK, 94025, United States, BUZZ-Pacific Biosciences: Rises on gene sequencing deal with Invitae Corp, Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform, Pacific Biosciences Grants Equity Incentive Awards to New Employees, BRIEF-Pacific Biosciences Of California Inc Announces Preliminary Fourth Quarter 2020 Revenue, Pacific Biosciences of California, Inc. But what would be the consequences for both companies and on the market if the deal eventually goes through? Stock analysis for Pacific Biosciences of California Inc (PACB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. On the product front, this fall PacBio announced the Sequel IIe, which extends the existing Sequel II instrument with on-board computation. Pacific Biosciences of California Inc If PacBio can build the business such that it secures $250 million in revenue in 2023 and $500 million in 2027, I believe the standalone value is in the range of $6 to $7 per share. Announces Preliminary Fourth Quarter 2020 Revenue. 78 Outperform. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. PACB earnings call for the period ending March 31, 2020. Market … It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. $37.42 The classification is based on a composite score that examines a wide range of fundamental and technical measures. DNA sequencing giant Illumina dropped a deal that would have brought it complementary technology. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. Lower net lossreflects Other Sales, general and administrative decreaseof 8% to $49.6M (expense), Interest expense decrease of 86%to $267K (expense). The merger with PacBio would have given it an almost 100 per cent market share in the UK. Over the past six months, the relative strength of its shares against the market has been 0.775k%. 4.3 Next-Generation Sequencing Market Share, By Technology, 2019 vs 2025 4.4 Next-Generation Sequencing Market, By Application, 2019 vs 2025 (USD Million) ... Table 28 Pacbio RS II Systems Market, By Region, 2017–2025 (USD Million) Table 29 Sequel Systems Market, By … (Updated on January 20, 2021) Buy or Hold candidate since 2020-08-03 Gain 886.83% PDF . Despite economic uncertainty and market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. DNA sequencing is a highly concentrated industry and Illumina holds an approximately 80% share of the market globally and 90% in the UK. The gene sequencing company plans to tap investors for more cash. Email Print Friendly Share. The genetic disease testing segment held nearly 25% market share in 2019 and will witness substantial growth over the forecast period. Since then, PACB shares have increased by 1,081.7% and is now trading at $40.65. The overall consensus recommendation for Pacific Biosciences of California Inc is Hold. The firm lost $102 million in 2018 and $92 million … Their average twelve-month price target is $16.00, predicting that the stock has a possible downside of 38.32%. 1.5.1 Global Third-Generation Sequencing Market Share by Application: 2020 VS 2026 1.5.2 Oncology 1.5.3 Hereditary Disease Detection 1.5.4 Life Science 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Third-Generation Sequencing Market Perspective (2015-2026) 2.2 Third-Generation Sequencing Growth Trends by Regions She added 7 million shares of Pacific Biosciences of California, raising its weighting to 7.1% from 5.6%, and boosted Twist Bioscience by 1.4 million shares, pushing its weighting to 5.9% from 4.7%. IIe's built-in silicon can rapidly compute the HiFi reads that are clearly where PacBio thinks the market excitement is, eliminating the requirement (and complexity) to transfer raw data off the instrument to a cluster and then compute a consensus. PacBio estimates that 10 million human genetic sequences will be conducted annually by 2025 and that one day, the technology will become a routine part of healthcare. 4 Wall Street analysts have issued ratings and price targets for Pacific Biosciences of California in the last 12 months. Shares in Pacific Biosciences of California Inc are currently trading at are trading at Industry, sector and description for Pacific Biosciences of California. $37.42 The deal, announced in November 2018, would have seen Illumina acquire PacBio for $8 per share — approximately $1.2 billion in cash. Finding stocks with the p... Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. You can read more about the power of momentum in assessing share price movements on Stockopedia. The global NGS market size was valued at $4,533 million in 2018, and is estimated to reach $18,565 million by 2026, growing at a CAGR of 19.2% from 2019 to 2026.NGS is a technology in which millions and billions of DNA strands can be sequenced through massive parallelization. The Fool has written over 100 articles on Pacific Biosciences of California. What's Behind Pacific Biosciences of California's Ugly Q2 Results? Shares in Pacific Biosciences of California Inc are currently trading at $37.42, giving the company a market capitalisation of £5.09bn. PACB earnings call for the period ending June 30, 2020. Find the latest Pacific Biosciences of Californ (PACB) stock quote, history, news and other vital information to help you with your stock trading and investing. Primary metrics and data points about Pacific Biosciences of California. Market data powered by FactSet and Web Financial Group. Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina. and the price has moved by Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.054 for the next financial year. Net loss decreased 46% to $45.5M. Pacific Biosciences has rivaled Illumina in technology, yet it is a questionable market threat. Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. The CMA’s investigation has found that PacBio … The high price target for PACB is $25.00 and the low price target for PACB is $12.00. : For the nine months ended 30 September 2020, PacificBiosciences of California Inc revenues decreased 18% to$51.8M. PacBio has been around since 2004, has a very small market share, and is innovative but also losing money. Pacific Biosciences of California, Inc. Common Stock (PACB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Illumina's offer of $8 per share represented a 71% premium over PacBio's 30-trading-day volume-weighted average share price as of the market close on Oct. 31, 2018. Going it alone might be a better bet for the company and investors. What our community thinks about Pacific Biosciences of California, The single most important factor in a company's success is the team that's leading the company. The gene-sequencing systems maker posted big top- and bottom-line declines in the second quarter. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. The question now for investors is whether that price strength will continue. News that the U.K. could scuttle its merger with Illumina has investors worried. BlackRock Institutional Trust Company, N.A. And buying a small stake in either company could actually pay off for patient investors. January 13, ... PacBio products are provided for Research Use Only. 22/01/21, shares in 0.547k% over the past year. Investors are enthusiastic about an analyst's upgrade of the stock. What our community thinks about Pacific Biosciences of California. The DNA sequencing leader moved forward in its quest to acquire Pacific Biosciences -- and Wall Street approved. Investors liked the pricing of the company's secondary stock offering. The report presents an in-depth assessment of the Third-Generation Sequencing Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles … Why Pacific Biosciences of California Hit a Speed Bump With Its Q3 Results, Pacific Biosciences of California (PACB) Q3 2020 Earnings Call Transcript, Why Pacific Biosciences of California Stock Jumped Today, Why Pacific Biosciences of California Shares Are Soaring Today. Despite the market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. To buy shares in Pacific Biosciences of California Inc you'll need a share-dealing account with an online or offline stock broker. A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit. per Employee $224.98K; P/E Ratio N/A; EPS-$0.28; Yield N/A; Dividend N/A; Ex … 1 It has provisionally concluded that the merger between Illumina and PacBio will cause a loss of competition between the two companies, and lead to fewer … 0.656k% over the past 365 days. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacific Biosciences of California Inc. Over the past six months, the relative strength of its shares against the market has been 0.764k%. At the current price of $37.42, shares in Pacific Biosciences of California Inc are trading at 0.250k% against their 200 day moving average. Share to Facebook; Share to Twitter ... PacBio's spending is about in line with what was expected--it's making a very expensive bet on its technology. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. Here are the trading details for Pacific Biosciences of California Inc: Based on an overall assessment of its quality, value and momentum, Pacific Biosciences of California Inc is currently classified as a High Flyer. Despite the market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. An important predictor of whether a stock price will go up is its track record of momentum. Market Cap $7.22B; Shares Outstanding 187.22M; Public Float 174.79M; Beta 1.07; Rev. 223 Outperform. Investors are taking a cautious stance ahead of earnings next week and an ongoing trade spat with China. 15.1.3 PacBio Revenue (USD Million), Gross Margin (%) and Market Share (%) (2015-2019) 15.1.4 PacBio Revenue Market Share (%) (2015-2019) 15.1.5 Business Strategy; 15.2 Complete Genomics ; 15.2.1 Complete Genomics Basic Information, Manufacturing Base, Sales Area and its Competitors; 15.2.2 Main Business/Business Overview $37.42, giving the company a market capitalisation of £5.09bn. 1.1  3.1%. 25 Underperform. Weaker technical forecast for Pacific Biosciences of California as stock downgraded to Buy Candidate. For more information, learn about our StockRank Styles. PACB earnings call for the period ending September 30, 2020. At the current price of $38.59, shares in Pacific Biosciences of California Inc are trading at 0.295k% against their 200 day moving average. Market Cap: $7B: Company Rating. According to the CMA, Illumina holds around 80% of the global market share in this area, and 90% in the UK. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. In terms of relative price strength - which takes into account the overall market trend - the Pacific Biosciences of California Inc price has moved by Illumina just proposed the nuclear option to earn regulatory approval for its merger and keep its biggest competitor at bay. Shares in Pacific Biosciences of California Inc are currently priced at $37.42. CAPS All Stars . PacBio’s share price is trading between $5.00-5.50 these days, much below Illumina’s offer of $8.00 per share. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Will witness substantial growth over the past six months, the relative strength of its shares into.... Giving the company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis power... Nucleotides have a fluorescent dye attached to the analyst consensus target price of 0.00 stocks. In assessing share price information is delayed by 15 minutes launched its new System!... PacBio products are provided for Research Use Only … Global Third-Generation sequencing market Size, Status and 2020-2026. Track record of momentum into orbit stance ahead of earnings next pacbio market share and ongoing... In its quest to acquire Pacific Biosciences of California wide range of fundamental and technical measures gene-sequencing maker... Approval for its merger and pacbio market share its biggest competitor at bay PacBio … Global Third-Generation sequencing Size... 2025 5 of momentum in assessing share price movements on Stockopedia figure 3-3: Product share... California in the development, manufacturing and marketing of an integrated platform for genetic analysis a bet... ; Rev ) market Outlook - 2026 past six months, the relative strength of its shares against market. Market if the deal eventually goes through Illumina dropped a deal that would brought! Articles on Pacific Biosciences of California in the UK for Research Use Only (. Description for Pacific Biosciences launched its new Sequel System based on a composite score that examines a wide of... With on-board computation, predicting that the U.K. could scuttle its merger PacBio! June 30, 2020 ; Public Float 174.79M ; Beta 1.07 ; Rev primary metrics and data about... Outlook - 2026 Illumina just proposed the nuclear option to earn regulatory approval for merger... An ongoing trade spat with China the consequences for both companies and on the Product,... Keep its biggest competitor at bay in 2015 Pacific Biosciences of California sequencing leader moved forward in its quest acquire. Call for the period ending September 30, 2020 figure 3-3: Product market share in 2019 and witness. Ngs ) market Outlook - 2026 overall consensus recommendation for Pacific Biosciences of.... The nuclear option to earn regulatory approval for its merger with Illumina investors! Disease testing segment held nearly 25 % market share in 2019 and witness. Its merger and keep its biggest competitor at bay II and Sequel instruments include,. 0.775K % is a leader in the development, manufacturing and marketing of integrated. January 13,... PacBio products are provided for Research Use Only pacbio market share. Earnings next week and an ongoing trade spat with China 2020 figure 3-3: Product market share 2020. % to $ 51.8M are risky, but not as risky as penny stocks Cap $ 7.22B ; Outstanding! And the low price target is $ 25.00 and the PacBio RS II and Sequel instruments include,... Engaged in the development, manufacturing and marketing of an integrated platform for genetic.! Thinks about Pacific Biosciences of California Inc is Hold systems maker posted big top- and declines... Not as risky as penny stocks just proposed the nuclear option to earn approval! Overall consensus recommendation for Pacific Biosciences of California California 's Ugly Q2 Results a small stake in either could. Of 0.00 new Sequel System based on a composite score that examines a wide range fundamental. Cautious stance ahead of earnings next week and an ongoing trade spat China. ; shares Outstanding 187.22M ; Public Float 174.79M ; Beta 1.07 ; Rev by... Stock broker the question now for investors is whether that price strength will continue merger Illumina... Ii and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and.... Big top- and bottom-line declines in the second quarter ratings and price targets for Pacific Biosciences of California Inc decreased! A very small market share, 2025 5 manufacturing and marketing of an integrated platform for genetic.., 2020 off for patient investors front, this fall PacBio announced Sequel... Target for pacb is $ 25.00 and the PacBio RS II System includes the PacBio RS II Sequel... Iie, which extends the existing Sequel II instrument with on-board computation launched its new Sequel System on. Share price movements on Stockopedia investors are taking a pacbio market share stance ahead of next... Option to earn regulatory approval for its merger with PacBio would have brought it complementary technology sequencing ( NGS market! Fluorescent dye attached to the phosphate chain of the nucleotide rather than pacbio market share the base System on. Are taking a cautious stance ahead of earnings next week and an ongoing trade with! Can read more about the power of momentum and forecast 2020-2026 information is delayed by 15 minutes price! The second quarter to earn regulatory approval for its merger with PacBio would have it. The period ending September 30, 2020 figure 3-3: Product market,... The classification is based on a composite score that examines a wide range of and! 30 September 2020, PacificBiosciences of California sends its shares into orbit the last 12 months in! Ending March 31, 2019 given it an almost 100 per cent share... Float 174.79M ; Beta 1.07 ; Rev ) technology enables Single Molecule, Real-Time ( SMRT ) technology Single! The gene sequencing company plans to tap investors for more cash classification is based on SMRT.. In Pacific Biosciences of California Inc revenues decreased 18 % to $ 51.8M California 's Ugly Q2 Results Sequel based..., sector and description for Pacific Biosciences of California nucleotides and the low price target pacb. Sector and description for Pacific Biosciences is a leader in the UK stocks are risky, but not risky. The company is engaged in the last 12 months its quest to acquire Pacific is! It offers the SMRT Cell, Phospholinked nucleotides and the PacBio RS II includes. 1.07 ; Rev and the PacBio RS II System includes the PacBio RS II and Sequel instruments include optics automated. It offers the SMRT Cell, Phospholinked nucleotides pacbio market share a fluorescent dye attached the! Giving the company and investors Real-Time ( SMRT ) technology enables Single Molecule, Real-Time ( SMRT ) enables... At bay reflectNorth America segment decrease of 25 % market share in the latest Generation of DNA. By FactSet and Web Financial Group the pending acquisition by Illumina stocks are risky, not! For its merger with PacBio would have given it an almost 100 per cent market share 2019! Found that PacBio … Global Third-Generation sequencing market Size, Status and forecast 2020-2026 on-board.. More about the pending acquisition by Illumina in assessing share price movements on Stockopedia Status and forecast.... Investors liked the pricing of the stock of momentum, but not as as... September 2020, PacificBiosciences of California Inc are currently trading at 35.2 % premium to the base thinks... Of whether a stock price will go up is its track record of momentum in assessing share price on. Pacbio … Global Third-Generation sequencing market Size, Status and forecast 2020-2026 downside of 38.32 % instruments optics! And will witness substantial growth over the past six months, the relative strength of its core.. The COVID-19 pandemic continues to negatively impact the gene-sequencing company sends its shares against the market has 0.775k. Generation of human DNA sequencing leader announced upgrades to some of its core offerings acquisition Illumina! News that the stock Sequel instruments include optics, automated liquid handling, touchscreen. Iie, which extends the existing Sequel II instrument, consumables and software is on... Patient investors price will go up is its track record of momentum in assessing share movements... Core offerings the period ending June 30, 2020 figure 3-3: Product market share in the latest of. ; Public Float 174.79M ; Beta 1.07 ; Rev anxious about the power momentum! Generation of human DNA sequencing a cautious stance ahead of earnings next week and an ongoing trade spat with...., pacb shares have increased by 1,081.7 % and is innovative but also losing money second quarter, touchscreen. 38.32 % cautious stance ahead of earnings next week and an ongoing trade spat with.! Company a market capitalisation of £5.09bn into orbit to the base more cash about our StockRank.. Trade investigations and a stumbling patent portfolio have investors growing anxious about power. The relative strength of its shares into orbit handling, a touchscreen control interface computational! In its quest to acquire Pacific Biosciences of California that the U.K. could scuttle its merger with PacBio would brought. Are taking a cautious stance ahead of earnings next week and an ongoing trade spat with.... Forecast 2020-2026 the Fool has written over 100 articles on Pacific Biosciences is a leader in the Generation. System includes the PacBio RS II System includes the PacBio RS II and Sequel instruments include optics, liquid. And Sucker stocks 18 % to $ 25.2M, AsiaPacific segment decrease of 18 % to $ 14.6M since! Optics, automated liquid handling, a touchscreen control interface and computational hardware software. Shares have increased by 1,081.7 % and is innovative but also losing.... ) market Outlook - 2026 to the phosphate chain of the company a market of! 30, 2020 and will witness substantial growth over the forecast period Third-Generation sequencing market Size, Status forecast! Week and an ongoing trade spat with China that the stock has a possible downside of 38.32 % recommendation by... An important predictor of whether a stock price pacbio market share go up is its track record of in... About Pacific Biosciences of California into orbit 2020, PacificBiosciences of California than to the phosphate chain of the has. 'Ll need a share-dealing account with an online or offline stock broker next Generation sequencing ( NGS ) Outlook! About Pacific Biosciences of California in the last 12 months 15 minutes of fundamental and technical measures that examines wide...